Development of a pharmacological target
β
Daniel V. Widzowski; Paul Bialobok; Kris E. Kucera; Roberta Mihut; Shawn Sitar;
π
Article
π
1997
π
John Wiley and Sons
π
English
β 178 KB
The purpose of these studies was to determine the levels of intrinsic activity in vitro at muscarinic receptor pharmacological subtypes (M 1 , M 2 , and M 3 ) that would optimize cognitive activity while minimizing acute adverse cholinergic effects in vivo. These levels of intrinsic efficacy at M 1